留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

生物制剂在炎症性肠病治疗中的矛盾性肠外表现研究进展

李章琴,  黄奇,  缪应雷

downloadPDF
文章导航 > 昆明医科大学学报  > 2024 >  45(2): 160-165
卿艳萍, 谭姝, 朱幼姗, 杨淑华. 中西医结合快速康复理念在结直肠外科围手术期护理的应用[J]. 昆明医科大学学报, 2016, 37(12): 148-150.
引用本文: 李章琴, 黄奇, 缪应雷. 生物制剂在炎症性肠病治疗中的矛盾性肠外表现研究进展[J]. 昆明医科大学学报, 2024, 45(2): 160-165. doi: 10.12259/j.issn.2095-610X.S20240223
shu
Qing Yan Ping , Tan Shu , Zhu You Shan , Yang Shu Hua . Application of Integrative Medicines of TCM and WM Combined with Fast-track Surgery Concept in Perioperative Nursing in Colorectal Surgery[J]. Journal of Kunming Medical University, 2016, 37(12): 148-150.
Citation: Zhangqin LI, Qi HUANG, Yinglei MIAO. Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease[J]. Journal of Kunming Medical University, 2024, 45(2): 160-165. doi: 10.12259/j.issn.2095-610X.S20240223
shu

生物制剂在炎症性肠病治疗中的矛盾性肠外表现研究进展

doi: 10.12259/j.issn.2095-610X.S20240223

  • 昆明医科大学第一附属医院消化内科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（82170550）
详细信息
    作者简介:

    李章琴（1998～），女，云南曲靖人，在读硕士研究生，主要从事炎症性肠病的临床诊疗工作

    通讯作者:

    缪应雷，E-mail： miaoyinglei@kmmu.edu.cn

  • 中图分类号: R574.62

Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease

  • Dept. of Gastroenterology，The 1st Affilited Hospital of Kunming Medical University，Kunming Yunnan 650032，China

摘要

    摘要
  • 摘要: 炎症性肠病（inflammatory bowel diseases，IBD）是一类由多基因及环境因素共同引起并加速免疫-肠道-微生态轴紊乱的遗传相关性疾病。病变常累及多个器官及系统.生物制剂是治疗IBD及其肠外表现的重要手段，目前研究多提示生物制剂能够为患者带来益处，但治疗过程中出现矛盾性皮肤病变、关节病变、眼部疾病、肺部病变等表现或病变在临床实践中容易被忽略，进而延误患者病情、影响患者生存质量。通过总结当前生物制剂应用出现的矛盾性肠外表现的临床特点及诊疗经验，旨在提高临床医师的认识，早期辨别这一临床表现，避免延误患者病情。
    Abstract: Inflammatory Bowel Diseases （IBD） is a class of genetically related diseases caused by multiple genes and environmental factors that accelerate the disturbance of the immune-gut-microbiome axis. Lesions often involve multiple organs and systems. Biological agents are an important means of treating IBD and its extraintestinal manifestations. Current studies suggest that biologics can bring benefits to patients, but paradoxical skin lesions, joint lesions, and ocular lesions appear during the treatment. Diseases, pulmonary lesions and other manifestations or lesions are easily ignored in clinical practice, thereby delaying the patient's condition and affecting the patient's quality of life. Therefore, by summarizing the clinical characteristics and diagnosis and treatment experience of contradictory extraintestinal manifestations in the current application of biological agents, this review aims to improve the understanding of clinicians, identify this clinical manifestation early, and avoid delaying the patient's condition.
    • HTML全文
    • 参考文献(50)
  • [1] Baumgart D C,Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease[J]. The New England Journal of Medicine,2021,385(14):1302-1315. doi: 10.1056/NEJMra1907607
    [2] Toussirot É,Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview[J]. RMD Open,2016,2(2):e000239. doi: 10.1136/rmdopen-2015-000239
    [3] Harbord M,Annese V,Vavricka S R,et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J]. Journal of Crohn’s & Colitis,2016,10(3):239-254.
    [4] Marzano A V,Borghi A,Stadnicki A,et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology,clinical features,and therapy[J]. Inflammatory Bowel Diseases,2014,20(1):213-227. doi: 10.1097/01.MIB.0000436959.62286.f9
    [5] Antonelli E,Bassotti G,Tramontana M,et al. Dermatological manifestations in inflammatory bowel diseases[J]. Journal of Clinical Medicine,2021,10(2):364. doi: 10.3390/jcm10020364
    [6] de Gannes G C,Ghoreishi M,Pope J,et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions[J]. Archives of Dermatology,2007,143(2):223-231.
    [7] Notley C A,Inglis J J,Alzabin S,et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells[J]. The Journal of Experimental Medicine,2008,205(11):2491-2497. doi: 10.1084/jem.20072707
    [8] Ma H L,Napierata L,Stedman N,et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells[J]. Arthritis and Rheumatism,2010,62(2):430-440. doi: 10.1002/art.27203
    [9] Schäffler H,Blattmann T,Findeisen A,et al. PAPA-Syndrom mit Morbus Crohn und primär sklerosierender Cholangitis/Autoimmunhepatitis-Overlap-Syndrom[J]. Der Hautarzt,2019,70(2):116-122. doi: 10.1007/s00105-018-4312-5
    [10] Cullen G,Kroshinsky D,Cheifetz A S,et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature: Anti-TNF-induced psoriasis in inflammatory bowel disease[J]. Alimentary Pharmacology & Therapeutics,2011,34(11-12):1318-1327.
    [11] Fréling E,Baumann C,Cuny J-F,et al. Cumulative incidence of,risk factors for,and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: A 14-year experience[J]. The American Journal of Gastroenterology,2015,110(8):1186-1196. doi: 10.1038/ajg.2015.205
    [12] Hu J Z,Billings S D,Yan D,et al. Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris[J]. Journal of the American Academy of Dermatology,2020,83(1):71-77. doi: 10.1016/j.jaad.2020.01.006
    [13] Cleynen I,Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD[J]. Nature Reviews Gastroenterology & Hepatology,2012,9(9):496-503.
    [14] Greuter T,Navarini A,Vavricka S R. Skin manifestations of inflammatory bowel disease[J]. Clinical Reviews in Allergy & Immunology,2017,53(3):413-427.
    [15] Rahier J-F,Buche S,Peyrin-Biroulet L,et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy[J]. Clinical Gastroenterology and Hepatology:The Official Clinical Practice Journal of the American Gastroenterological Association,2010,8(12):1048-1055. doi: 10.1016/j.cgh.2010.07.022
    [16] Flendrie M,Vissers W H P M,Creemers M C W,et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study[J]. Arthritis Research & Therapy,2005,7(3):R666-676.
    [17] Chang Y-C,Yang H-J. Successful management of tumor necrosis factor-alpha inhibitor-induced Sweet syndrome in a patient with ulcerative colitis: A case report[J]. Int. Journal of Clinical Pharmacology and Therapeutics,2022,60(01):46-51. doi: 10.5414/CP204088
    [18] Lu S,Yao J,Zhi M. Therapeutic effect of ustekinumab on patients with extra-intestinal manifestations of Crohn’s disease[J]. Expert Review of Gastroenterology & Hepatology,2023,17(4):379-384.
    [19] Nguyen E D,Gabel C K,Kroshinsky D. Assessing the incidence of skin and soft tissue infection in patients on biologics[J]. Journal of the American Academy of Dermatology,2021,85(3):604-610. doi: 10.1016/j.jaad.2020.03.128
    [20] Ezzedine K,Visseaux L,Cadiot G,et al. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study[J]. The Journal of Dermatology,2019,46(4):322-327. doi: 10.1111/1346-8138.14816
    [21] Kolios A G A,Biedermann L,Weber A,et al. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab[J]. The British Journal of Dermatology,2018,178(2):551-555. doi: 10.1111/bjd.15631
    [22] Tadbiri S,Peyrin-Biroulet L,Serrero M,et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort[J]. Alimentary Pharmacology & Therapeutics,2018,47(4):485-493.
    [23] Rogler G,Singh A,Kavanaugh A,et al. Extraintestinal manifestations of inflammatory bowel disease: Current concepts,treatment,and implications for disease management[J]. Gastroenterology,2021,161(4):1118-1132. doi: 10.1053/j.gastro.2021.07.042
    [24] Karreman M C, Luime J J, Hazes J M W, et al. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis[J]. Journal of Crohn’s and Colitis, 2017,11（5）: 631-642.
    [25] Thiebault H,Boyard-Lasselin P,Guignant C,et al. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab[J]. European Journal of Gastroenterology & Hepatology,2016,28(8):876-881.
    [26] Fiorino G,Danese S,Pariente B,et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents[J]. Autoimmunity Reviews,2014,13(1):15-19. doi: 10.1016/j.autrev.2013.06.005
    [27] Alivernini S,Pugliese D,Tolusso B,et al. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis[J]. RMD Open,2018,4(1):e000667. doi: 10.1136/rmdopen-2018-000667
    [28] Bryant R V,Winer S,Travis S P L,et al. Systematic review: histological remission in inflammatory bowel disease. Is “complete” remission the new treatment paradigm? An IOIBD initiative[J]. Journal of Crohn’s & Colitis,2014,8(12):1582-1597.
    [29] Sondag M,Verhoeven F,Guillot X,et al. “Paradoxical” arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease[J]. Joint Bone Spine,2018,85(1):133-134. doi: 10.1016/j.jbspin.2017.01.001
    [30] Üsküdar Cansu D,Üsküdar Teke H,Temel T,et al. Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? real life data[J]. Journal of the National Medical Association,2019,111(3):262-269. doi: 10.1016/j.jnma.2018.10.003
    [31] Cachen L,Nocturne G,Collins M,et al. Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF[J]. RMD open,2022,8(1):e001697. doi: 10.1136/rmdopen-2021-001697
    [32] Noordenbos T,Yeremenko N,Gofita I,et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis[J]. Arthritis and Rheumatism,2012,64(1):99-109. doi: 10.1002/art.33396
    [33] Puig L. Paradoxical reactions: Anti-tumor necrosis factor alpha agents,ustekinumab,secukinumab,ixekizumab,and others[J]. Current Problems in Dermatology,2018,53:49-63.
    [34] Onsun N,Yalcin B,Sallahoglu K,et al. Worsening of psoriatic arthritis after ustekinumab treatment[J]. American Journal of Therapeutics,2018,25(3):e381-e382. doi: 10.1097/MJT.0000000000000546
    [35] Stamell E F,Kutner A,Viola K,et al. Ustekinumab associated with flares of psoriatic arthritis[J]. JAMA Dermatology,2013,149(12):1410-1413. doi: 10.1001/jamadermatol.2013.5728
    [36] Garc í a Garc í a M J,Rivero Tirado M,Callizo M E P. Paradoxical arthritis in inflammatory bowel diasease patients on ustekinumab treatment[J]. Inflammatory Bowel Diseases,2019,25(7):e89. doi: 10.1093/ibd/izz019
    [37] De Galan C,Truyens M,Peeters H,et al. The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study[J]. Journal of Crohn’s and Colitis,2022,16(11):1676-1686.
    [38] Ottaviano G,Salvatore S,Salvatoni A,et al. Ocular manifestations of paediatric inflammatory bowel disease: A systematic review and meta-analysis[J]. Journal of Crohn’s and Colitis,2018,12(7):870-879. doi: 10.1093/ecco-jcc/jjy029
    [39] Gionchetti P,Dignass A,Danese S,et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations[J]. Journal of Crohn’s & Colitis,2017,11(2):135-149.
    [40] Vavricka S R,Brun L,Ballabeni P,et al. Frequency and risk factors for extraintestinal manifestations in the swiss inflammatory bowel disease cohort[J]. American Journal of Gastroenterology,2011,106(1):110-119. doi: 10.1038/ajg.2010.343
    [41] Iwahashi C,Ono H,Haruta M,et al. New onset or exacerbation of uveitis with infliximab: paradoxical effects?[J]. BMJ Open Ophthalmology,2019,4(1):e000250. doi: 10.1136/bmjophth-2018-000250
    [42] Clemmensen K,Akrawi N,Stawowy M. Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis[J]. Scandinavian Journal of Gastroenterology,2015,50(12):1508-1511. doi: 10.3109/00365521.2015.1063155
    [43] Garcia-Medina J J,Pastor-Grau A,del-Rio-Vellosillo M,et al. Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-year follow-up[J]. Scandinavian Journal of Gastroenterology,2016,51(6):765-766. doi: 10.3109/00365521.2015.1126855
    [44] Matet A,Daruich A,Beydoun T,et al. Systemic adalimumab induces peripheral corneal infiltrates: A case report[J]. BMC Ophthalmology,2015,15:57. doi: 10.1186/s12886-015-0047-6
    [45] Jordan D R,Park J S Y,Al-Breiki D. Acute orbital inflammation with loss of vision: a paradoxical adverse event associated with infliximab therapy for Crohn’s disease[J]. Orbit,2021,41(6):791-796.
    [46] Gîlcă G-E,Diaconescu S,Bălan G Gh,et al. Sarcoidosis associated with infliximab therapy in ulcerative colitis: A case report[J]. Medicine,2017,96(10):e6156. doi: 10.1097/MD.0000000000006156
    [47] Murdaca G,Spanò F,Contatore M,et al. Infection risk associated with anti-TNF-α agents: a review[J]. Expert Opinion on Drug Safety,2015,14(4):571-582. doi: 10.1517/14740338.2015.1009036
    [48] the BIOGEAS Study Group,Bosch X,Saiz A,et al. Monoclonal antibody therapy-associated neurological disorders[J]. Nature Reviews Neurology,2011,7(3):165-172. doi: 10.1038/nrneurol.2011.1
    [49] Brigo F,Bongiovanni L G,Cerini R,et al. Infliximab-related seizures: A first case study[J]. Epileptic Disorders,2011,13(2):214-217. doi: 10.1684/epd.2011.0439
    [50] Calafat M,Mañosa M,Ricart E,et al. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease: A cohort study of the ENEIDA registry[J]. Journal of Crohn’s & Colitis,2022,16(6):946-953.
    • 相关文章(20)
  • [1] 张瀚予, 罗娟, 董明志, 陈杞殷, 张峰睿, 郭蕊, 童俊英, 缪应雷.  英夫利西单抗及维得利珠单抗治疗中重度溃疡性结肠炎的回顾性队列研究, 昆明医科大学学报.
    [2] 张瀚予, 罗娟, 董明志, 陈杞殷, 张峰睿, 郭蕊, 童俊英, 缪应雷.  英夫利西单抗及维得利珠单抗治疗中重度溃疡性结肠炎的回顾性队列研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241006
    [3] 李波, 孙杨, 缪应雷.  炎症性肠病的肠道微生态变化及对策, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240401
    [4] 聂忠顺, 缪应雷.  生物制剂背景下粪菌移植对炎症性肠病的应用前景, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241023
    [5] 杨顺航, 李炯明, 刘建和, 王光, 李沛.  肠源性高草酸尿症的发病机制与治疗进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220734
    [6] 阮艳琴, 李茂涓, 和丽梅, 宋莹, 黄巧云, 陈莹, 刘畅.  以患者为主的炎症性肠病患者PRO量表特异模块条目筛选, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220310
    [7] 刘蓉, 孙杨, 罗发梦, 陶德智, 张海燕.  炎症性肠病患者疾病接受度与生存质量的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220507
    [8] 刘幸, 李海雯, 黄红丽, 沈凌筠, 张乐, 刘向芳, 张文林, 王璐.  益生菌强化肠内营养支持对重症急性胰腺炎患者胃肠道功能和炎症因子的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211116
    [9] 蒋迁, 孙宇, 霍丽珺, 雷雅燕, 裴洛伟.  微酸性电解水对根管内粪肠球菌生物膜抗菌作用的体外研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210303
    [10] 熊普, 张尊月, 王昆华.  成瘾性物质致肠屏障损伤的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210131
    [11] 向盈盈, 于鸿滨, 周静, 杨向红, 宋飞, 魏云林, 季秀玲.  致病性粪肠球菌YN771的分离鉴定及其生物学特性, 昆明医科大学学报.
    [12] 黄治国, 殷维, 晏毅.  瑞芬太尼抑制大鼠炎症性疼痛及其机制, 昆明医科大学学报.
    [13] 张安兴, 吴静, 孙杨, 缪应雷.  炎症性肠病宿主遗传变异与肠道微生物的联系, 昆明医科大学学报.
    [14] 孙杨.  英夫利西单抗治疗炎症性肠病的临床分析, 昆明医科大学学报.
    [15] 叶世华.  全肠内营养在克罗恩病治疗的回顾, 昆明医科大学学报.
    [16] 杨绍芬.  谷氨酰胺强化肠内营养治疗非感染性腹泻临床疗效分析, 昆明医科大学学报.
    [17] 艾佳.  新型糖皮质激素在炎症性肠病治疗中有效性和安全性的研究现状, 昆明医科大学学报.
    [18] 刘艳.  炎症性肠病与生育, 昆明医科大学学报.
    [19] 李敏丽.  炎症性肠病与精神心理因素相关性研究, 昆明医科大学学报.
    [20] 杨阳.  憩室性直疝伴肠脂垂嵌顿后脂肪瘤变1例, 昆明医科大学学报.
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1144
  • HTML全文浏览量:  448
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-12-29
  • 刊出日期:  2024-02-25

目录

摘要
HTML全文
    参考文献(50)
    相关文章(20)
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有 © 《昆明医科大学学报》编辑部  滇ICP备00000000号-0

    编辑出版：昆明医科大学学报编辑部

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计